Kyunghee Lee and Sayed S. Daoud
Abstract:
There are few reports describing the role of p21-dependent protein repression in cell death. To identify such cell death-associated proteins and to shed the light into the molecular mechanisms by which p21 is responding to pharmacological stress, we used a subcellular proteomic approach for the analysis of protein expression profiles of fractionated nuclei, mitochondria, and cytosols of isogenic p21 null (p21-/-) and wild-type human HCT-116 cells following treatment with sublethal doses (1μM) of the topoisomerase I inhibitor, topotecan (TPT). In total, 174 unique deregulated proteins were identified in HCT-116 cells following treatment with TPT, whereas only 146 proteins were identified in p21-/- cells. They contributed to multiple functional activities of stress signaling pathways, and that p21-/- cells are accelerated to be more responsive to topotecan-induced cell death due to the following: 1) down regulation of proteins involved in the transcriptional and replication machinery of cells like DNA (cytosine-5)-methyltransferase 1, Matrin 3, DNA replication licensing factor MCM4, heterogeneous nuclear ribonucleoprotein Q, poly(Rc)-binding protein 1 and splicing factor arginine serine rich 7; 2) the activation of a caspase-independent apoptosis by the upregulation of the Bcl2 inhibitor of transcription (Bit1) protein; and 3) the activation of TNF signaling by the upregulation of macrophage immigration inhibitory factor (MIF), and 26S proteosome non-ATPase regulatory subunit 2 (TRAP2) proteins. We suggest that the upregulation of these proteins are contributing factors to the molecular mechanisms of topotecan-induced cell death in p21-/- cells; and that the data present an opportunity for developing new therapeutic approaches for selective targeting of p21-
signaling pathways.
Key Words: Proteomics, topotecan, p21, colon cancer, mass spectrometry, Bit1
Download Full Article HERE
